Business
George Medicines advances its global commercial strategy for GMRx2 with an exclusive licensing agreement with Orient EuroPharma in Southeast Asia
GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an established safety profileGeorge Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, along with a future recurring revenue stream through stepped royalties in Southeast AsiaFourth licensing and supply agreement for GMRx2 reflects continued glob
About this update from Orient Europharma Co., Ltd.
[{"type":"image","alt":"George Medicines","displaySize":"","headline":null,"caption":"George Medicines","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/ac9086adeb02e0db25420838713379c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7BsyEtZyTwf_TZF46lhpMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ac9086adeb02e0db25420838713379c7","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an established safety profile","length":227,"tagName":"p"}]},{"val":[{"type":"text","content":"George Medicines receives upfront licensing fee and is eligible for regulatory and commercial milestone payments, along with a future recurring revenue stream through stepped royalties in Southeast Asia","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth licensing and supply agreement for GMRx2 reflects continued global partner interest, with further partnerships anticipated as George Medicines advances its strategy to expand global patient access","length":203,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":632,"olType":false},{"type":"text","content":"London, UK, 25 February 2026 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Orient EuroPharma (“OEP”) (TWO: 4120), a leading multinational pharmaceutical company headquartered in Taiwan, granting OEP exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Southeast Asia.","length":452,"tagName":"p"},{"type":"text","content":"GMRx2 is an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. Its multi-mechanism approach and available doses are formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the...